EC approves MabThera for chronic lymphocytic leukaemia
The European Commission (EC) has approved the subcutaneous formulation of Roche’s MabThera (rituximab) for people with previously untreated and relapsed/refractory chronic lymphocytic leukaemia (CLL).
Click on this link for more information.
